Source: http://www.google.es/patents/US8337890
Timestamp: 2017-12-18 10:49:53
Document Index: 500857807

Matched Legal Cases: ['Application No. 07', 'Application No. 07', 'Application No. 07', 'Application No. 07', 'Application No. 11192711', 'Application No. 2007227569', 'application No. 2008140944', 'Application No. 2009', 'Application No. 194042']

Patente US8337890 - Modified release formulations containing drug-ion exchange resin complexes - Google Patentes
A coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The drug-ion exchange resin complex is in admixture with a release retardant. The coating is a polyvinyl acetate polymer and a plasticizer. Methods...http://www.google.es/patents/US8337890?utm_source=gb-gplus-sharePatente US8337890 - Modified release formulations containing drug-ion exchange resin complexes
Número de publicación US8337890 B2
Número de solicitud US 12/722,857
También publicado como CA2645855A1, CA2645855C, CN101400343A, CN101400343B, CN102488652A, CN102488652B, EP2018160A2, EP2018160B1, EP2428205A1, EP2428205B1, US8062667, US8202537, US8491935, US8597684, US8747902, US8790700, US8883217, US9198864, US9522191, US9549989, US9675703, US9675704, US20070215511, US20100166858, US20120015030, US20130059007, US20130136797, US20140030334, US20140056984, US20140127306, US20150024059, US20150272893, US20160158373, US20160310438, US20160310449, US20160310478, US20170100487, US20170274088, WO2007109104A2, WO2007109104A3
Número de publicación 12722857, 722857, US 8337890 B2, US 8337890B2, US-B2-8337890, US8337890 B2, US8337890B2
Cesionario original Tris Pharma Inc
Citas de patentes (138), Otras citas (137), Citada por (21), Clasificaciones (52), Eventos legales (3)
US 8337890 B2
(i) a particulate matrix comprising a particulate drug-ion exchange resin complex and a water insoluble polymer or copolymer, or a hydrophilic polymer, said particulate matrix capable of passing through a number 40 mesh screen,
said drug-ion exchange resin complex comprising a pharmaceutically acceptable drug bound to a pharmaceutically acceptable water insoluble ion exchange resin to form said drug-ion exchange resin complex, said ion exchange resin being irregularly shaped and selected from
(A) a copolymer comprising styrene and divinylbenzene and
(B) a copolymer comprising sytrene and divinylbenzene having quaternary ammonium functional groups,
wherein said water insoluble polymer or copolymer, or hydrophilic polymer, is present in an amount of about 3% to about 30% by weight, based on the weight of said drug-ion exchange resin complex defined in (i), and
(ii) a cured, high tensile strength, water permeable, water insoluble, non-ionic polymeric diffusion modified release barrier coating over said particulate drug-ion exchange resin complex—water insoluble polymer or copolymer, or hydrophilic polymer matrix defined in (i), said cured barrier coating applied as an aqueous dispersion and comprising
(a) about 75% w/w to about 90% w/w polyvinylacetate polymer
(c) about 2.5 to about 20% w/w of plasticizer effective to enhance the tensile strength of said cured barrier coating, whereby said cured coating provides a modified release profile to the drug in said drug-ion exchange resin complex in said matrix.
said drug-ion exchange resin complex comprising a pharmaceutically acceptable drug bound to a pharmaceutically acceptable water insoluble ion exchange resin to form a said drug-ion exchange resin complex, said ion exchange resin being irregularly shaped and selected from
(c) at least an amount of plasticizer effective to enhance the tensile strength of said cured barrier coating, whereby said cured coating provides a modified release profile to the drug in said drug-ion exchange resin complex in said matrix.
US6551620 * 16 Jul 2001 22 Abr 2003 Dr. Falk Pharma Gmbh Pellet formulation for the treatment of the intestinal tract
JPH02172912A Título no disponible
1 Active Ingredients References, (Feb. 9, 2006) pp. 1, www.F:/Heathcare-Website/active-refl..htm, (Feb. 9, 2006).
2 Active Ingredients References, (Feb. 9, 2006) pp. 1, www.F:/Heathcare—Website/active—refl..htm, (Feb. 9, 2006).
4 Active Ingredients, Ion Exchange Resins-Healthcare, Rohm Haas, pp. 1, www.F:/Heathcare—Website/deliquescence.htm, (Feb. 9, 2006).
6 Amberlite IRP and Duolite AP Ion Exchange Resins, Ion Exchange Resins-Healthcare, Rohm Haas, pp. 1, www.F:/Heathcare—Website/formulations—products.htm, (Feb. 9, 2006).
7 Amberlite IRP and Duolite AP143 Applications Reference List, Rohm Haas Ion Exchange Resins-Healthcare, www.rohmhaas.com, (Dec. 1, 2004).
8 Amberlite IRP and Duolite AP143 Ion Exchange Resins Bulk Pharmaceutical Chemicals for Finished Dosage Forms, pp. 1-2, Healthcare Website/release refl.htm, (Feb. 2, 2006).
9 Amberlite IRP64 Pharmaceutical Grade Cation Exchange Resin, Product Data Sheet, pp. 1-3, (Sep. 2004).
10 Amberlite IRP69 Pharmaceutical Grade Cation Exchange Resin, Product Data Sheet, pp. 1-4, (Nov. 2004).
11 Amberlite IRP69 Pharmaceutical Grade, 54OES, (Feb. 2006).
13 Amendment, Response and Declaration, filed Mar. 7, 2012 in response to NFOA on Dec. 23, 2011 in U.S. Appl. No. 13/244,706.
14 Amendment, Response and Declaration, filed Mar. 9, 2012 in response to NFOA of Dec. 9, 2011 in U.S. Appl. No. 13/244,748.
16 Aoyama, T., et al., "Pharmacodynamic Modeling for Change of Locomotor Activity by Methylphenidate in Rats", 1997, Pharmaceutical Research, vol. 14, No. 11, pp. 1601-1606.
17 BASF ExAct, A New Sustained Release Excipient, p. 2, No. 3, (Nov. 1999).
18 BASF Pharma Solutions:Excipients by Trademark, Kollicoat®, BASF website www.pharma-solutions.basf.com, pp. 1-3, (Dec. 2, 2004).
20 BASF-Expertise in Health and Nutrition, Sustained Release Excipients, p. 1-13, Kollicoat® SR 30 D, Tackiness of Films as a Function of Type and Concentration of Plasticizer, Aug. 2007.
21 Bordaweka, M.S., and Zia, H, Evaluation of Polyvinyl Acetate Dispersion as a Sustained Release Polymer for Tablets, Drug Delivery, 13(2):121-131, (Mar. and Apr. 2006).
22 Bordawekar et al, Evaluation of Kollicoat® SR 30D as a Sustained Release Polymer Dispersion, BASF Corporation, University of Rhode Island, p. 25, AAPS Poster, (2002).
23 Borodokin, Polycarboxylic Avid Ion-Exchange Resin Adsorbates for Taste Coverage in Chewable Tablets, J. Pharm. Sci. vol. 60, No. 10, pp. 1523-1527 (Oct. 1971).
24 Childress, AC, et al., "The Single-Dose Pharmacokinetics of NWP06, a Novel Extended-Release Methylphenidate Oral Suspension", Postgraduate Medicine, vol. 122, Issue 5, Sep. 2010, pp. 35-41.
25 Communication dated Jan. 5, 2009 corresponding to EP Application No. 07 753 217.4.
26 Communication dated Jan. 7, 2011 corresponding to EP Application No. 07 753 217.4.
27 Communication dated Nov. 22, 2010 and response dated Mar. 25, 2011 corresponding to EP Application No. 07 753 217.4.
28 Communication dated Nov. 26, 2008 and response dated Dec. 17, 2008 corresponding to EP Application No. 07 753 217.4.
29 Dashevsky et al, Compression of Pellets Coated with Various Aqueous Polymer Dispersions, International Journal of Pharmaceutics, 279(1-2):19-26, (Jul. 26, 2004).
30 Dashevsky et al, Physicochemical and Release Properties of Pellets Coated with Kollicoat SR 30 D, a New Aqueous Polyvinyl Acetate Dispersion for Extended Release, International Journal of Pharmaceutics, 290(1-2):15-23. (Feb. 16, 2005) Epublication: Jan. 6, 2005.
31 Declaration Pursuant to 37 CFR 1.132 by Dr. Kibbe and Declaration Pursuant to 37 CFR 1.132 by Dr. Tu filed in U.S. Appl. No. 11/724,966.
32 Degussa, Creating Essentials, Specifications and Test Methods for EUDRAGIT® NE 30 D, p. 1-4, (Sep. 2004).
33 Deliquescent Drugs, Ion Exchange Resins-Healthcare, Rohm Haas, pp. 1, www.F:/Heathcare-Website/deliquescence.htm, (Feb. 9, 2006).
34 Deliquescent Drugs, Ion Exchange Resins-Healthcare, Rohm Haas, pp. 1, www.F:/Heathcare—Website/deliquescence.htm, (Feb. 9, 2006).
35 Dissolution Enhancement of Poorly Soluble Drugs, Ion Exchange Resins-Healthcare, Rohm Haas, www.F:/Heathcare-Website/Solubility.htm, (Feb. 9, 2006).
36 Dissolution Enhancement of Poorly Soluble Drugs, Ion Exchange Resins-Healthcare, Rohm Haas, www.F:/Heathcare—Website/Solubility.htm, (Feb. 9, 2006).
40 Eliminating Polymorphism, Ion Exchange Resins-Healthcare, Rohm Haas, www.F:/Heathcare-Website/polymorph.htm, (Feb. 9, 2006).
41 Eliminating Polymorphism, Ion Exchange Resins-Healthcare, Rohm Haas, www.F:/Heathcare—Website/polymorph.htm, (Feb. 9, 2006).
42 El-Samaligy et al, Formulation and Evaluation of Sustained-Release Dextromethorphan Resinate Syrup, Egypt J. Pharm. Sci., 37, No. 1-6, pp. 509-519, (1996).
43 Erdmann et al, Coating of Different Drugs with Optimized Kollicoat EMM 30 D Coatings, BASF Aktiengesellschaft, Proceedings of the 26th CRS symposium, (Jun. 1999), 6313.
44 Extended European Search Report dated Feb. 1, 2012 issued in counterpart European Patent Application No. 11192711.7.
45 Extended Release, RohmHaas Ion Exchange Resins-Healthcare, p. 1, Rohm and Haas website, www.rohmhaas.com, (Feb. 9, 2005).
46 FDA, Excipient Workshop, (Sep. 20, 2004).
47 First Examiners Report dated Nov. 28, 2011 issued in corresponding Australian Patent Application No. 2007227569.
48 Generic Drug Formulations with Kollicoat® SR 30 D and Kollidon® SR, pp. 1-51, BASF, 1999.
49 Guide-Choosing the Right Functional Polymer, pp. 1, www.F:/Heathcare-Website/guide.htm (Feb. 9, 2006).
50 Guide-Choosing the Right Functional Polymer, pp. 1, www.F:/Heathcare—Website/guide.htm (Feb. 9, 2006).
53 Hughes, Ion Exchange Resins Unique Solutions to Formulation Problems, pp. 3, Rohm Haas, (2004).
54 Hughes, New Uses of Ion Exchange Resins in Pharmaceutical Formulation, Rohm Haas, (2004).
55 Ichikawa et al, Use of Ion-Exchange Resins to Prepare 100 mum-Sized Microcapsules with Prolonged Drug-Release by the Wurster Process, International Journal of Pharmaceutics 216, pp. 67-76, (2001).
56 Ichikawa et al, Use of Ion-Exchange Resins to Prepare 100 μm-Sized Microcapsules with Prolonged Drug-Release by the Wurster Process, International Journal of Pharmaceutics 216, pp. 67-76, (2001).
57 Improved Dissolution of Poorly Soluble Drugs References, pp. 1, www.F:/Heathcare-Website/Poor-Solubility-refl.htm, (Feb. 9, 2006).
58 Improved Dissolution of Poorly Soluble Drugs References, pp. 1, www.F:/Heathcare—Website/Poor—Solubility—refl.htm, (Feb. 9, 2006).
59 International Search Report and the Written Opinion of the International Search Report of International Application No. PCT/US2011/024873.
60 International Search Report dated Jan. 10, 2007.
61 Ion Exchange Resins-Healthcare, Rohm Haas, Frequently Asked Questions, pp. 1-3, www.F:/Heathcare-Website/gaq-print.htm, (Feb. 9, 2006).
62 Ion Exchange Resins-Healthcare, Rohm Haas, Frequently Asked Questions, pp. 1-3, www.F:/Heathcare—Website/gaq—print.htm, (Feb. 9, 2006).
63 Iron Exchange Resins, GB/US-(Jan. 2004).
64 Iron Exchange Resins, GB/US—(Jan. 2004).
65 Kollicoat SR30D, Technical Information, (Jan. 2004, Supercedes Jun. 1999).
66 Kollicoat SR30D, Technical Information, Bulletin, MEV96, (Jun. 1999).
67 Kollicoat SR30D, Technical Information, ME36(e), pp. 1-14, (Jun. 1999).
68 Kollicoat SR30D, Technical Information, MEMP30(e)-01, pp. 1-13, (Jan. 2004).
69 Kollicoat® SR 30 D, Polyvinyl Acetate Dispersion for Sustained-Release Pharmaceutical Formulations, Technical Information, BASF, (Jun. 1999).
70 Kollicoat®-Film-Coating Technology by BASF, www.pharma-solutions.basf.com, (Dec. 2, 2004).
71 Kollicoat®—Film-Coating Technology by BASF, www.pharma-solutions.basf.com, (Dec. 2, 2004).
77 Kolter et al, Kollicoat® SR 30 D A New Sustained Release Excipient, BASF AG, (Nov. 1999).
80 Mies, D., et al, BASF, "Pharmasolutions", MEMPD 130, Correlation of Drug Permeation Through Isolated Films and Coated Dosage Forms Based on Kollicoat 30SR D/IR, 2004 ASPS Annual Meeting and Exposition, (Nov. 7-11, 2004).
81 Nicotine, Ion Exchange Resins-Healthcare, Rohm Haas, www.F:/Heathcare-Website/nicotin.htm, (Feb. 9, 2006).
82 Nicotine, Ion Exchange Resins-Healthcare, Rohm Haas, www.F:/Heathcare—Website/nicotin.htm, (Feb. 9, 2006).
83 Nisar-Ur-Rahman et al, Differential Scanning Calorimetry and Surface Morphology Studies on Coated Pellets using Aqueous Dispersions, Pakistan Journal of Pharmaceutical Sciences, 18(2):19-23, (Apr. 2005).
84 Non-Final Office Action with Response dated Mar. 12, 2010 corresponding to U.S. Appl. No. 11/724,966.
85 Notice of Allowance dated Aug. 19, 2011 with response corresponding to U.S. Appl. No. 11/724,966.
86 Novartis Consumer Health in Canada, DELSYM, www.Novartisconsumerhealth.ca/en/products/delsym.shtml, Novartis Consumer Health Inc., copyright (2003).
87 Office Action and Response with translation dated Mar. 30, 2011 corresponding to the Russian counterpart application No. 2008140944.
88 Office Action issued in counterpart JP Patent Application No. 2009-500494, with translation of Notice of Reasons for Rejection, bibliography from official gazettes, and excerpts of four "references".
89 Office Action, dated Dec. 23, 2011, issued in U.S. Appl. No. 13/244,706.
90 Office Action, dated Dec. 9, 2011, issued in U.S. Appl. No. 12/722,857, corresponding to US-2010-0166858-A1.
91 Office Action, dated Dec. 9, 2011, issued in U.S. Appl. No. 13/244,748 corresponding to US-2012-0015030 A1.
92 Office Action, dated Feb. 21, 2012, issued in U.S. Appl. No. 13/244,766 corresponding to US Published Patent Application No. US-2012-0015030-A1.
93 Pearnchob, N., et al, "Coating with Extended Release", ExACT, No. 12, Jun. 2004, pp. 2-5.
94 Polymorphism References, pp. 1, www.F:/Heathcare-Website/polymorph-references.htm, (Feb. 9, 2006).
95 Polymorphism References, pp. 1, www.F:/Heathcare—Website/polymorph—references.htm, (Feb. 9, 2006).
96 Product Literature, Concerta®, (methylphenidate HC1) Extended-release Tablets, rev Nov. 2010.
97 Product Literature, Daytrana(TM) (methylphenidate transdermal system), revised Dec. 2009.
98 Product Literature, Daytrana™ (methylphenidate transdermal system), revised Dec. 2009.
99 Product Literature, Focalin™ XR (dexmethylphenidate hydrochloride) extended-release capsules, 2004.
100 Product Literature, Once Daily Metadate CD™ (methylphenidate HC1, USP) Extended-Release Capsules, Feb. 2007.
101 Product Literature, Ritalin® hydrochloride methylphenidate hydrochloride tablets USP and Ritalin-SR® methylphenidate hydrochloride USP sustained-release tablets, revised Dec. 2010.
102 Publications-Ion Exchange Resins-Healthcare, Rohm Haas, www.F:/Heathcare-Website/publications.htm, (Feb. 9, 2006).
103 Publications-Ion Exchange Resins-Healthcare, Rohm Haas, www.F:/Heathcare—Website/publications.htm, (Feb. 9, 2006).
104 Quadir, Anisul, FDA Excipient Workshop, "Development of High Functionality Excipients for Immediate and Sustained Release Dosage Forms", (Sep. 20, 2004).
105 Raghunathan et al, Sustained-release Drug Delivery System 1: Coated ion-exchange Resin System for Phenylpropanolamine and Other Drugs, J. Pharm Sci, vol. 70, pp. 379-384, (Apr. 1981).
106 Reduced Abuse Formulations, Ion Exchange Resins-Healthcare, Rohm Haas, www.F:/Heathcare-Website/reduced-Abuse.htm, (Feb. 9, 2006).
107 Reduced Abuse Formulations, Ion Exchange Resins-Healthcare, Rohm Haas, www.F:/Heathcare—Website/reduced—Abuse.htm, (Feb. 9, 2006).
108 Response to Office Action with translation dated Apr. 5, 2011 corresponding to the Israeli Patent Application No. 194042.
109 Robinson, J., Sustained and Controlled Release Drug Delivery Systems, Drugs and the Pharmaceutical Sciences, A Series of Textbooks and Monographs, vols. 1-6, pp. 130-210, Copyright 1978 by Marcel Dekker, Inc., New York and Basel.
110 Rowe, Materials Used in the Film Coating of Oral Dosage Forms, Crit. Rep. Appl. Chem., 6:1-16 (1984).
111 Sawicki, W. and Lunio, R., Compressibility of Floating Pellets with Verapamil Hydrochloride Coated with Dispersion Kollicoat SR 30 D, European Journal of Pharmaceutics and Biopharmaceutics, 60(1):153-8, (May 2005) Epublication: Jan. 8, 2005.
112 Seong Hoon Jeong et al, Drug Release Properties of Polymer Coated Ion-Exchange Resin Complexes: Experimental and Theoretical Evaluation, Journal of Pharmaceutical Sciences, pp. 1-15, (Apr. 2006).
113 Seong Hoong Jeong, "Evaluation of Drug Release Properties from Polymer Coated Drug/Ion-Exchange Resin Complexes Using Mathematical Simulation and Their Application into Sustained Oral Drug Delivery", Department of Pharmaceutical Chemistry, University of Kansas, Abstract, (Jun. 16-18, 2005).
114 Seong Hoong Jeong, Development of Sustained Release Fast-melting Tablets Using Ion Exchange Resin Complexes Dissertations, Submitted to Purdue University, W. Lafayette, Indiana, pp. 92-105, 114, 141, 142,169, UMI #3210729, (Dec. 2005).
115 Shao et al, Drug Release Form Kollicoat SR 30D-Coated Nonpareil Beads: Evaluation of Coating Level, Plasticizer Type, and Curing Condition, pp. 1-9, PharmSci Tech, 3(2):article 15, (Jun. 2002).
116 Shao et al, Effects of Formulation Variables and Post-Compression Curing on Drug Release from a New Sustained-Release Matrix Material: Polyvinylacetate-Povidone, Pharmaceutical Development and Technology, 6(2):247-254, (2001).
117 * Shao, AAPS PharmSciTech, 2002.
118 Strübing et al, Mechanistic Analysis of Drug Release From Tablets with Membrane Controlled Drug Delivery, European Journal of Pharmaceutics and Biopharmaceuticals, 66(1):113-9, (Apr. 2007) Epublication: Sep. 28, 2006.
119 Swarbrick, J., "Suspensions" in Remington: The Science and Practice of Pharmacy, 20th Edition, ed. By A.R. Gennaro et al, Lippincott, 2000, pp. 316-323.
120 Table Disintegrate, Ion Exchange Resins-Healthcare, Rohm Haas, pp. 1, www.F:/Heathcare-Website/deliquescence.htm, (Feb. 9, 2006).
121 Table Disintegrate, Ion Exchange Resins-Healthcare, Rohm Haas, pp. 1, www.F:/Heathcare—Website/deliquescence.htm, (Feb. 9, 2006).
122 Taste Masking References, www.F:/Heathcare-Website/taste-refl.htm, (Feb. 9, 2006).
123 Taste Masking References, www.F:/Heathcare—Website/taste—refl.htm, (Feb. 9, 2006).
124 Taste Masking, Ion Exchange Resins-Healthcare, Rohm Haas, pp. 1, www.F:/Heathcare-Website/tastemasking.htm, (Feb. 9, 2006).
125 Taste Masking, Ion Exchange Resins-Healthcare, Rohm Haas, pp. 1, www.F:/Heathcare—Website/tastemasking.htm, (Feb. 9, 2006).
126 U.S. Appl. No. 60/468,449, filed May 7, 2003.
127 U.S. Appl. No. 60/624,959, filed Nov. 4, 2004.
128 Unpublished U.S. Appl. No. 12/154,970, filed May 28, 2008.
129 Unpublished U.S. Appl. No. 12/261,349, Mehta et al, filed Oct. 30, 2008.
130 Unpublished U.S. Appl. No. 12/908,796, Mehta et al, filed Oct. 20, 2010.
131 Unpublished U.S. Appl. No. 13/244,706, filed Sep. 26, 2011.
132 Unpublished U.S. Appl. No. 13/244,748, filed Sep. 26, 2011.
133 US 7,431,994, 10/2008, Mehta (withdrawn)
134 US Office Action dated Jun. 23, 2010 and Response from corresponding U.S. Appl. No. 11/724,966.
135 US Office Action dated Nov. 26, 2010 and Response from corresponding U.S. Appl. No. 11/724,966.
136 Voskoboinikova et al, Drug Synthesis Methods and Manufacturing Technology, Modern Auxiliary Substances in Tablet Production: Use of High-Molecular-Weight Compounds for the Development of New Medicinal Forms and Optimization of Technological Processes, Pharmaceutical Chemistry Journal, 39(1):22-28, (Jan. 2005).
137 Water Permeability of Kollicoat EMM 30 D and Eudragit NE 30 D, p. 1, Oct. 28, 2004.
Clasificación de EE.UU. 424/469, 424/78.14, 424/78.13, 424/78.16, 424/487, 424/78.1
Clasificación internacional A61K47/48, A61K9/00, A61K9/32
Clasificación cooperativa A61K47/48853, A61K45/06, A61K9/167, A61K9/5021, A61K47/48876, A61K47/489, A61K47/48169, A61K47/585, A61K47/6927, A61K47/6933, A61K47/14, A61K31/4458, A61K47/48184, A61K31/137, A61K31/24, A61K9/1635, A61K9/4866, A61K9/0053, A61K9/2081, A61K9/0095, A61K9/2031, A61K9/2027, A61K9/2013, A61K9/14, A61K31/4402, A61K47/32, A61K9/5026, A61K9/0056, A61K31/192, A61K31/216, A61K31/135, A61K9/1664, A61K9/10, A61K31/155, A61K9/2077, A61K31/485
Clasificación europea A61K47/48K4D, A61K9/50H6B, A61K9/20K2B, A61K9/16H8, A61K9/00M18B, A61K9/10, A61K9/20K2